Search clinical trials for: IBI112 dose 1

Total 19725 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI302 in Patients With nAMD

Neovascular Age-related Macular Degeneration

China
University of Minnesota

Recruiting

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Solid Organ Transplant

United States
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Study of TAS3731 in Healthy Adults

Healthy Adult Males

Japan
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Zensun Sci. & Tech. Co., Ltd.
Zensun USA Inc.

Completed

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)

Chronic Heart Failure

United States
Shanghai Municipal Center for Disease Control and...
Shanghai Institute Of Biological Products

Unknown

Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine

Varicella

China
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
Oryn Therapeutics, LLC

Completed

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

Rheumatoid Arthritis

United States
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
Renibus Therapeutics, Inc.

Completed

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (START)

AKI

United States, Australia, Canada
Aronora, Inc.

Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
Pharnext SA

Completed

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT)

Charcot-Marie-Tooth Disease Type 1A

United States, United Kingdom, Belgium, Canada, France, Netherlands, Spain, Germany
Ehab L Atallah

Recruiting

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Acute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic Leukemia

United States
University of Sao Paulo General Hospital

Completed

Impact of Low Dose Fluoroscopy in Ureteroscopy

Ureteral Stone

Brazil
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (SAPHIRA2)

Cystic Fibrosis

Belgium, Netherlands
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Oryn Therapeutics, LLC

Withdrawn

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

COVID-19

United States
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Cystic Fibrosis

United Kingdom, Australia, Ireland, Germany, Czech Republic
Aronora, Inc.

Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Thrombosis

United States
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Avanir Pharmaceuticals

Completed

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

Healthy

Australia
Gerbera Therapeutics, Inc.

Not yet recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (NuMom)

Postpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal Depression

United States
ObsEva SA

Completed

OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI (IMPLANT)

Infertility

Poland, United Kingdom, Spain, Belgium, Denmark, Czechia
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG2222

Healthy

Belgium
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Mineralys Therapeutics Inc.

Recruiting

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Hypertension

United States, Italy, Germany, Australia, Canada, United Kingdom, Puerto Rico, Bulgaria, Spain
Arthrosi Therapeutics

Completed

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

Hyperuricemia | Gout | Arthritis, Gouty | Gout Chronic

United States, Australia, Taiwan
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

Influenza

Mexico
Biocad

Recruiting

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B

Russian Federation
Epeius Biotechnologies

Completed

Phase II Study of Intravenous Rexin-G in Osteosarcoma

Osteosarcoma

United States
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada

Search clinical trials for: IBI112 dose 1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations